Lumito AB signs a Letter of Intent with Katana Labs GmbH

Lumito has signed a "Letter of Intent” with Katana Labs in Germany to offer a cloud and AI-based image analysis solution to Lumito's future customers with "scanning-service agreements". For potential customers to easily evaluate Lumito's product SCIZYS, a "scanning service" is offered. This enables customers to evaluate the benefits of SCIZYS without first investing in […]

Lumito AB publishes Quarterly Report 2, 2024

First half of the year1 January – 30 June 2024 Net sales amounted to KSEK 17 (0). Result after taxes amounted to KSEK -15,244 (-14,668). Basic and diluted earnings per share amounted to SEK -0,06 (-0,07). Cash flow from operating activities after change in working capital amounted to KSEK -16,247 (-13,734). Cash and cash equivalents […]

Lumito has CE-marked its first product SCIZYS

Lumito has CE-marked its first product, SCIZYS. This is an important milestone for Lumito and means that sales for the histopathological research market can begin. SCIZYS S1 now fulfils all the relevant provisions of the EC Machinery Directive 2006/42/EC. The internal work required to be able to CE mark the product after receiving the final […]

Lumito AB publishes Quarterly Report 1, 2024

Financial overview of the first quarter January 1 to March 31, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -7 113 (-7 245). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -7 180 […]

Lumito AB publishes Quarterly Report 4, 2023

Financial overviewFourth quarterOctober 1 – December 31, 2023 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -5 777 (-6 612). Earnings per share before and after dilution amounted to SEK -0,03 (-0,03). Cash flow from operating activities after changes in working capital amounted to TSEK -5 480 (-5 153). Full […]

Lumitos issue of warrants is fully subscribed multiple times

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]